Fmr LLC Buys 101,182 Shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)

Fmr LLC grew its stake in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) by 1.9% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 5,329,902 shares of the company’s stock after buying an additional 101,182 shares during the quarter. Fmr LLC owned approximately 0.09% of Harmony Biosciences worth $183,402,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. JPMorgan Chase & Co. grew its stake in shares of Harmony Biosciences by 68.4% during the third quarter. JPMorgan Chase & Co. now owns 230,428 shares of the company’s stock valued at $9,217,000 after buying an additional 93,622 shares during the last quarter. Swiss National Bank grew its position in Harmony Biosciences by 28.2% during the 4th quarter. Swiss National Bank now owns 78,200 shares of the company’s stock worth $2,691,000 after acquiring an additional 17,200 shares during the last quarter. Teacher Retirement System of Texas increased its stake in Harmony Biosciences by 50.6% in the 4th quarter. Teacher Retirement System of Texas now owns 11,801 shares of the company’s stock worth $406,000 after purchasing an additional 3,964 shares during the period. Vanguard Group Inc. lifted its position in Harmony Biosciences by 36.4% in the fourth quarter. Vanguard Group Inc. now owns 4,733,609 shares of the company’s stock valued at $162,883,000 after purchasing an additional 1,262,362 shares during the last quarter. Finally, Barclays PLC boosted its stake in shares of Harmony Biosciences by 110.9% during the third quarter. Barclays PLC now owns 76,862 shares of the company’s stock valued at $3,074,000 after purchasing an additional 40,416 shares during the period. Institutional investors own 86.23% of the company’s stock.

Insiders Place Their Bets

In other news, insider Jeffrey Dierks sold 1,629 shares of the business’s stock in a transaction that occurred on Monday, January 27th. The stock was sold at an average price of $38.02, for a total transaction of $61,934.58. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CFO Sandip Kapadia sold 25,000 shares of the stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $40.18, for a total transaction of $1,004,500.00. The disclosure for this sale can be found here. Insiders have sold a total of 72,452 shares of company stock valued at $2,831,679 in the last quarter. 30.80% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

A number of research firms recently commented on HRMY. Deutsche Bank Aktiengesellschaft began coverage on shares of Harmony Biosciences in a report on Tuesday, February 11th. They set a “buy” rating and a $55.00 price target for the company. Mizuho increased their target price on shares of Harmony Biosciences from $42.00 to $44.00 and gave the stock an “outperform” rating in a report on Tuesday, March 18th. HC Wainwright restated a “buy” rating and set a $70.00 price target on shares of Harmony Biosciences in a report on Tuesday, April 8th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $50.00 price objective on shares of Harmony Biosciences in a report on Tuesday, April 8th. Nine analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Harmony Biosciences presently has an average rating of “Buy” and an average target price of $53.33.

Harmony Biosciences Stock Performance

HRMY opened at $29.17 on Friday. The company has a 50 day simple moving average of $33.89 and a two-hundred day simple moving average of $34.80. The company has a debt-to-equity ratio of 0.28, a current ratio of 3.24 and a quick ratio of 3.20. The firm has a market cap of $1.67 billion, a P/E ratio of 13.82, a PEG ratio of 0.47 and a beta of 0.80. Harmony Biosciences Holdings, Inc. has a 1-year low of $26.47 and a 1-year high of $41.61.

Harmony Biosciences (NASDAQ:HRMY) last issued its earnings results on Tuesday, February 25th. The company reported $0.85 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.74 by $0.11. Harmony Biosciences had a return on equity of 23.16% and a net margin of 17.98%. The company had revenue of $201.30 million for the quarter, compared to the consensus estimate of $201.25 million. During the same quarter last year, the company earned $0.45 EPS. The firm’s quarterly revenue was up 19.5% on a year-over-year basis. Equities analysts forecast that Harmony Biosciences Holdings, Inc. will post 2.43 earnings per share for the current fiscal year.

About Harmony Biosciences

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.